Published in Ann Neurol on January 01, 2003
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Frontotemporal dementias: a review. Ann Gen Psychiatry (2007) 1.11
Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. J Int Neuropsychol Soc (2008) 1.03
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother (2011) 0.91
Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat (2011) 0.83
Paranoid personality masking an atypical case of frontotemporal dementia. J Clin Med Res (2015) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Neurodegenerative diseases target large-scale human brain networks. Neuron (2009) 9.69
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain (2010) 3.84
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol (2003) 3.66
Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol (2003) 3.20
Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology (2005) 3.14
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol (2005) 3.11
Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron (2012) 3.07
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol (2007) 3.04
Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol (2008) 3.03
Rapidly progressive dementia. Ann Neurol (2008) 3.00
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Neuroanatomical correlates of behavioural disorders in dementia. Brain (2005) 2.92
Unravelling Boléro: progressive aphasia, transmodal creativity and the right posterior neocortex. Brain (2007) 2.75
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain (2007) 2.72
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol (2009) 2.68
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol (2006) 2.38
Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol (2005) 2.36
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Structural anatomy of empathy in neurodegenerative disease. Brain (2006) 2.28
Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol (2006) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol (2013) 2.26
Heritability of lobar brain volumes in twins supports genetic models of cerebral laterality and handedness. Proc Natl Acad Sci U S A (2002) 2.24
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Connected speech production in three variants of primary progressive aphasia. Brain (2010) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Diagnosis of human prion disease. Proc Natl Acad Sci U S A (2005) 2.13
Sporadic Creutzfeldt-Jakob disease mimicking variant Creutzfeldt-Jakob disease. Arch Neurol (2003) 2.12
Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry (2006) 2.10
Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. Neuroradiology (2008) 2.09
White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain (2009) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol (2007) 2.02
Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging (2011) 2.01
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Case records of the Massachusetts General Hospital. Case 9-2015. A 31-year-old man with personality changes and progressive neurologic decline. N Engl J Med (2015) 1.97
Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol (2005) 1.91
Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain (2013) 1.91
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Longitudinal MRI and cognitive change in healthy elderly. Neuropsychology (2007) 1.88
Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem (2011) 1.88
Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex (2011) 1.87
Clinicopathological correlations in corticobasal degeneration. Ann Neurol (2011) 1.86
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2013) 1.84
Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging (2005) 1.83
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain (2008) 1.82
Continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol (2007) 1.81
Progressive nonfluent aphasia and its characteristic motor speech deficits. Alzheimer Dis Assoc Disord (2007) 1.78
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry (2013) 1.74
White matter damage in primary progressive aphasias: a diffusion tensor tractography study. Brain (2011) 1.73
Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs (2010) 1.72
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology (2012) 1.69
Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol (2013) 1.68
Heightened emotional contagion in mild cognitive impairment and Alzheimer's disease is associated with temporal lobe degeneration. Proc Natl Acad Sci U S A (2013) 1.67
Perioperative cognitive decline in the aging population. Mayo Clin Proc (2011) 1.66
Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias. Neurology (2013) 1.65
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol (2008) 1.59
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep (2003) 1.58
Rapidly progressive dementia. Neurol Clin (2007) 1.58
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol (2007) 1.57
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging (2007) 1.57
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol (2007) 1.57
Automated MRI-based classification of primary progressive aphasia variants. Neuroimage (2009) 1.55
Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: reciprocal networks and neuronal evolution. Alzheimer Dis Assoc Disord (2007) 1.55
Double dissociation of social functioning in frontotemporal dementia. Neurology (2003) 1.54
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Language networks in semantic dementia. Brain (2009) 1.50
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A (2009) 1.49